FLSM
PLRX icon

Frazier Life Sciences Management’s Pliant Therapeutics PLRX Stock Holding History

Frazier Life Sciences Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,120,803
Closed -$14.8M – 54
2024
Q4 		$14.8M Buy
+1,120,803
New +$15.3M 0.61% 32

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Frazier Life Sciences Management's PLRX Position: Q1 2025 in Review

Frazier Life Sciences Management sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 1,120,803 shares — an estimated $14.8M sold.

Frazier Life Sciences Management first reported a position in PLRX in Q4 2024 and held it in 1 quarter. The position peaked at $14.8M in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Frazier Life Sciences Management reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Frazier Life Sciences Management sold 1,120,803 Pliant Therapeutics shares in Q1 2025, an estimated $14.8M.
  • Frazier Life Sciences Management first reported a position in Pliant Therapeutics in Q4 2024 and held it in 1 quarter.
  • Frazier Life Sciences Management's Pliant Therapeutics position peaked at $14.8M in Q4 2024.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Frazier Life Sciences Management's 13F filing for Q1 2025, filed 15 May 2025.